Being exposed at work to medium or high levels of asbestos is associated with a near double risk of developing…
Articles by Marisa Wexler, MS
The U.S. Food and Drug Administration (FDA) has granted INS018_055 orphan drug designation for the treatment of idiopathic pulmonary fibrosis…
The Phase 3 REBUILD clinical trial testing INOpulse (inhaled nitric oxide) in people with pulmonary fibrosis (PF) has enrolled…
A new startup company called Isterian Biotech has launched with the goal of developing new therapies for fibrotic diseases. Isterian…
A Phase 2b clinical trial testing NP-120 (ifenprodil) as a treatment for chronic cough is expected to begin later this…
Treatment with an extract of scorpion venom eased lung scarring in a mouse model of pulmonary fibrosis (PF), a…
Pliant Therapeutics’ experimental oral anti-fibrotic therapy bexotegrast has received orphan drug designation from the European Medicines Agency (EMA) as…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ifenprodil, the active agent in NP-120, an…
Dosing has begun in healthy volunteers in a Phase 1 clinical trial evaluating the safety and pharmacological properties of LASN01,…
Treatment with Haduvio (nalbuphine extended-release tablets) significantly reduced coughing for people with idiopathic pulmonary fibrosis (IPF), according to top-line…